Sermorelin Vs Ipamorelin: A Comparison
Product List
Sermorelin
cjc and ipamorelin side effects Ipamorelin are two of the most frequently discussed peptides within the anti‑aging and clinical hormone replacement communities. The product line typically includes:
Sermorelin – a synthetic analogue of growth hormone‑releasing hormone (GHRH) that stimulates endogenous GH secretion.
Ipamorelin – a selective growth hormone secretagogue that binds to the ghrelin receptor, promoting GH release without affecting cortisol or prolactin levels.
Combined formulations – many suppliers offer dual‑peptide kits allowing simultaneous administration of Sermorelin and Ipamorelin for synergistic effects.
Dilution kits – ready‑to‑use syringes with pre‑measured concentrations for convenient dosing.
These products are available in various vial sizes, typically ranging from 1 mg to 5 mg per vial, and can be purchased directly through the company’s online portal or via licensed distributors.
Sermorelin vs. Ipamorelin: A comparison
Both peptides share the common goal of increasing growth hormone (GH) levels, but they differ in mechanism, pharmacokinetics, side‑effect profile, and clinical applications.
Mechanism of actionSermorelin mimics natural GHRH, binding to receptors on pituitary somatotrophs. This triggers the release of GH in a pulsatile manner that closely resembles physiological secretion patterns.
Ipamorelin is a ghrelin‑like secretagogue; it binds to growth hormone secretagogue receptor 2 (GHS-R2), stimulating GH release directly from the pituitary and also enhancing insulin‑like growth factor‑1 (IGF‑1) production.
Onset and durationSermorelin’s effects typically begin within 30–60 minutes after subcutaneous injection, with a half‑life of about 90 minutes.
Ipamorelin acts more rapidly, often peaking at around 15–20 minutes post‑injection, and has a shorter half‑life (~45 minutes).
Dosage schedulesSermorelin is usually prescribed in doses ranging from 100 to 300
